The Carlat Psychiatry Podcast
A New Option for Bipolar Depression
Lumateperone (Caplyta) just got FDA approved for bipolar depression. Find out how it compares to other atypical antipsychotics.
Published On: 01/24/2022
Duration: 24 minutes, 09 seconds
Chris Aiken, MD, and Kellie Newsome, PMHNP, have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Got feedback? Take the podcast survey.